AbbVie Ordered To Pay $3M In AndroGel Retrial

Law360, Chicago (March 26, 2018, 4:13 PM EDT) -- An Illinois federal jury on Monday found AbbVie Inc.'s AndroGel product caused an Oregon man's heart attack and ordered the company to pay him more than $3 million, a verdict that came in the latest bellwether trial in the multidistrict litigation over testosterone replacement therapy drugs.

The verdict came at the end of a more than two-week trial and was the second time a jury has considered whether the man's heart attack was caused by his AndroGel use. Shown is an unrelated 2007 arbitration hearing. (AP) The jury awarded plaintiff Jesse Mitchell $200,000 in compensatory damages and $3 million in punitive damages...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Related Sections

Case Information

Case Title

Subscribers Only

Case Number

Subscribers Only

Court

Subscribers Only

Nature of Suit

Subscribers Only

Judge

Subscribers Only

Date Filed

Subscribers Only

Law Firms

Companies

Government Agencies

Judge Analytics

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!